Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review
- 1 September 2021
- journal article
- review article
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (5) , 103126
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Update on Recurrent Respiratory PapillomatosisOtolaryngologic Clinics of North America, 2019
- Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two childrenThe Laryngoscope, 2018
- Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a childThe Laryngoscope, 2016
- Recurrent respiratory papillomatosis: current and future perspectivesTherapeutics and Clinical Risk Management, 2015
- Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosisOncology Letters, 2014
- Use of Adjuvant Intralesional Bevacizumab for Aggressive Respiratory Papillomatosis in ChildrenJAMA Otolaryngology–Head & Neck Surgery, 2013
- Local Injection of Bevacizumab (Avastin) and Angiolytic KTP Laser Treatment of Recurrent Respiratory Papillomatosis of the Vocal Folds: A Prospective StudyAnnals of Otology, Rhinology & Laryngology, 2011
- Recurrent respiratory papillomatosis: update 2008Current Opinion in Otolaryngology & Head and Neck Surgery, 2008
- Role of Vascular Endothelial Growth Factor–A in Recurrent Respiratory PapillomatosisAnnals of Otology, Rhinology & Laryngology, 2005
- National Registry for Juvenile-Onset Recurrent Respiratory PapillomatosisJAMA Otolaryngology–Head & Neck Surgery, 2003